Antimicrobial agents and chemotherapy

publication venue for

PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. 2014
Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program. 2023
Unlocking the Potential of Bacteriophage to Prevent Recurrent Urinary Tract Infections after Kidney Transplantation. 2023
Functional Diversity of Gram-Negative Permeability Barriers Reflected in Antibacterial Activities and Intracellular Accumulation of Antibiotics. 2023
Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits. 2022
Susceptibilities of Ugandan Plasmodium falciparum Isolates to Proteasome Inhibitors. 2022
Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity.. 66. 2022
Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents. 2022
Pharmacokinetics, Tissue Distribution, and Efficacy of VIO-001 (Meropenem/Piperacillin/Tazobactam) for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia in Immunocompetent Rabbits with Chronic Indwelling Vascular Catheters.. 65. 2021
Synergistic Action between PfHsp90 Inhibitor and PfRad51 Inhibitor Induces Elevated DNA Damage Sensitivity in the Malaria Parasite.. 65. 2021
Elevated MICs of Susceptible Anti-Pseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization. 2021
Characterization of Differentially Detectable Mycobacterium tuberculosis in the Sputum of Subjects with Drug-Sensitive or Drug-Resistant Tuberculosis before and after Two Months of Therapy.. 65. 2021
Analysis of Multidrug Resistance in Staphylococcus aureus with a Machine Learning-Generated Antibiogram.. 65. 2021
Limited Utility of Procalcitonin in Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease 2019.. 65. 2021
Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of Candida Endophthalmitis and Hematogenous Meningoencephalitis in Nonneutropenic Rabbits.. 65. 2021
Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy.. 65. 2021
Antifungal Activity of Gepinacin Scaffold Glycosylphosphatidylinositol Anchor Biosynthesis Inhibitors with Improved Metabolic Stability.. 64. 2020
Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents.. 64. 2020
Activity of Epigenetic Inhibitors against Plasmodium falciparum Asexual and Sexual Blood Stages.. 64. 2020
A Histone Methyltransferase Inhibitor Can Reverse Epigenetically Acquired Drug Resistance in the Malaria Parasite Plasmodium falciparum.. 64. 2020
Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.. 64. 2020
Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis.. 64. 2020
Tissue Distribution of Doxycycline in Animal Models of Tuberculosis.. 64. 2020
Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.. 64. 2020
Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV.. 64. 2020
Amphotericin B Penetrates into the Central Nervous System Through Focal Disruption of the Blood Brain Barrier in Experimental Hematogenous Candida Meningoencephalitis.. 63. 2019
Cost-effectiveness of ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae bacteremia and pneumonia. 2019
Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae.. 63. 2019
Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance.. 63. 2019
Spheroplast-Mediated Carbapenem Tolerance in Gram-Negative Pathogens.. 63. 2019
Isolation of Phage Lysins That Effectively Kill Pseudomonas aeruginosa in Mouse Models of Lung and Skin Infection.. 63. 2019
U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016.. 63. 2019
Lysocins: Bioengineered Antimicrobials That Deliver Lysins across the Outer Membrane of Gram-Negative Bacteria.. 63. 2019
Molecular Analysis of Resistance and Detection of Non-Wild-Type Strains Using Etest Epidemiological Cutoff Values for Amphotericin B and Echinocandins for Bloodstream Candida Infections from a Tertiary Hospital in Qatar.. 62. 2018
Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits.. 62. 2018
Genetic Determinants of High-Level Oxacillin Resistance in Methicillin-Resistant Staphylococcus aureus.. 62. 2018
Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis.. 62. 2018
Chemical Genetic Interaction Profiling Reveals Determinants of Intrinsic Antibiotic Resistance in Mycobacterium tuberculosis.. 61. 2017
Effects of HIV-1 Tat and Methamphetamine on Blood-Brain Barrier Integrity and Function In Vitro.. 61. 2017
Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.. 61. 2017
Antibiotic Resistance as a Stress Response: Recovery of High-Level Oxacillin Resistance in Methicillin-Resistant Staphylococcus aureus "Auxiliary" (fem) Mutants by Induction of the Stringent Stress Response.. 61. 2017
Evolutionary Origin of the Staphylococcal Cassette Chromosome mec (SCCmec).. 61. 2017
High-Level Resistance of Staphylococcus aureus to β-Lactam Antibiotics Mediated by Penicillin-Binding Protein 4 (PBP4).. 61. 2017
Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States.. 61. 2017
New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae.. 61. 2017
Full-Genome Sequencing Identifies in the Genetic Background Several Determinants That Modulate the Resistance Phenotype in Methicillin-Resistant Staphylococcus aureus Strains Carrying the Novel mecC Gene.. 61. 2017
Evaluation of a Multiplex PCR Assay To Rapidly Detect Enterobacteriaceae with a Broad Range of β-Lactamases Directly from Perianal Swabs.. 60. 2016
Monitoring Antimicrobial Resistance in the Food Supply Chain and Its Implications for FDA Policy Initiatives.. 60. 2016
Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3.. 60. 2016
In Vitro and In Vivo Characterization of the Novel Oxabicyclooctane-Linked Bacterial Topoisomerase Inhibitor AM-8722, a Selective, Potent Inhibitor of Bacterial DNA Gyrase.. 60. 2016
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus.. 60. 2016
Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.. 60. 2016
Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.. 60. 2016
Role of the Stringent Stress Response in the Antibiotic Resistance Phenotype of Methicillin-Resistant Staphylococcus aureus.. 60. 2016
Klebsiella pneumoniae Isolate from a New York City Hospital Belonging to Sequence Type 258 and Carrying blaKPC-2 and blaVIM-4.. 60. 2016
Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model.. 60. 2015
Using a Novel Lysin To Help Control Clostridium difficile Infections.. 59. 2015
Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods.. 59. 2015
Role of urine neutrophil gelatinase-associated lipocalin in the early diagnosis of amphotericin B-induced acute kidney injury.. 59. 2015
HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument.. 59. 2015
Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis.. 59. 2015
U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.. 59. 2015
Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City.. 59. 2015
Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City.. 59. 2015
Incidence, Predictors, and Impact on Hospital Mortality of Amphotericin B Nephrotoxicity Defined Using Newer Acute Kidney Injury Diagnostic Criteria.. 59. 2015
Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach.. 59. 2015
Kidney injury associated with telavancin dosing regimen in an animal model.. 59. 2015
Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.. 59. 2015
Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City.. 59. 2014
Identification and characterization of linezolid-resistant cfr-positive Staphylococcus aureus USA300 isolates from a New York City medical center.. 58. 2014
In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.. 58. 2014
Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.. 58. 2014
Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents.. 58. 2014
Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B.. 58. 2014
Host biomarkers of invasive pulmonary aspergillosis to monitor therapeutic response.. 58. 2014
Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis.. 57. 2013
Identification of extended-spectrum-β-lactamase-positive Klebsiella pneumoniae urinary tract isolates harboring KPC and CTX-M β-lactamases in nonhospitalized patients.. 57. 2013
Pharmacokinetic and in vivo efficacy studies of the mycobactin biosynthesis inhibitor salicyl-AMS in mice.. 57. 2013
Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus.. 57. 2013
Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis.. 57. 2013
KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy.. 57. 2012
Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.. 57. 2012
A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections.. 56. 2012
Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells.. 56. 2012
Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design.. 56. 2012
Multiplex real-time PCR for detection of an epidemic KPC-producing Klebsiella pneumoniae ST258 clone.. 56. 2012
Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009.. 56. 2012
Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.. 56. 2012
Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.. 56. 2012
Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.. 56. 2011
Simulated antibiotic exposures in an in vitro hollow-fiber infection model influence toxin gene expression and production in community-associated methicillin-resistant Staphylococcus aureus strain MW2.. 56. 2011
Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine.. 55. 2011
A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and -sensitive Staphylococcus aureus strains.. 55. 2010
Polymyxin-resistant clinical isolates of Escherichia coli.. 55. 2010
The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.. 54. 2010
Identification of a novel transposon (Tn6072) and a truncated staphylococcal cassette chromosome mec element in methicillin-resistant Staphylococcus aureus ST239.. 54. 2010
In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli.. 54. 2010
Effect of antifungal therapy timing on mortality in cancer patients with candidemia.. 54. 2009
Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children.. 54. 2009
Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections.. 53. 2009
Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.. 53. 2009
Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis.. 53. 2009
Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.. 53. 2009
Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections.. 53. 2008
Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.. 53. 2008
Cerebrospinal fluid and plasma (1-->3)-beta-D-glucan as surrogate markers for detection and monitoring of therapeutic response in experimental hematogenous Candida meningoencephalitis.. 52. 2008
Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores.. 52. 2008
Comparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole.. 52. 2008
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.. 52. 2008
Role of a sodium-dependent symporter homologue in the thermosensitivity of beta-lactam antibiotic resistance and cell wall composition in Staphylococcus aureus.. 52. 2007
Characterization and dynamics of middle ear fluid and nasopharyngeal isolates of Streptococcus pneumoniae from 12 children treated with levofloxacin.. 52. 2007
Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.. 52. 2007
Fluorescence ratio imaging microscopy shows decreased access of vancomycin to cell wall synthetic sites in vancomycin-resistant Staphylococcus aureus.. 51. 2007
Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.. 51. 2007
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.. 51. 2007
Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.. 50. 2006
Role of VraSR in antibiotic resistance and antibiotic-induced stress response in Staphylococcus aureus.. 50. 2006
Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis.. 50. 2006
Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.. 50. 2006
Inhibition of the autolytic system by vancomycin causes mimicry of vancomycin-intermediate Staphylococcus aureus-type resistance, cell concentration dependence of the MIC, and antibiotic tolerance in vancomycin-susceptible S. aureus.. 50. 2006
Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.. 49. 2005
Fluoroquinolone-resistant Streptococcus agalactiae: epidemiology and mechanism of resistance.. 49. 2005
Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits.. 49. 2005
Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis.. 49. 2005
Penicillin-binding protein 2 is essential for expression of high-level vancomycin resistance and cell wall synthesis in vancomycin-resistant Staphylococcus aureus carrying the enterococcal vanA gene complex.. 48. 2004
Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin.. 48. 2004
Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans.. 48. 2004
Quinolone-resistant Haemophilus influenzae in a long-term-care facility: nucleotide sequence characterization of alterations in the genes encoding DNA gyrase and DNA topoisomerase IV.. 48. 2004
Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread.. 48. 2004
Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.. 48. 2004
In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.. 48. 2004
Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.. 48. 2004
Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits.. 47. 2003
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.. 47. 2003
Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis.. 47. 2003
Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States.. 47. 2003
In vitro activities of newer quinolones against bacteroides group organisms.. 46. 2002
Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum.. 46. 2002
Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus.. 46. 2002
Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.. 46. 2002
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.. 46. 2002
Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.. 46. 2002
Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.. 45. 2001
Cloning and biochemical characterization of FOX-5, an AmpC-type plasmid-encoded beta-lactamase from a New York City Klebsiella pneumoniae clinical isolate.. 45. 2001
Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.. 45. 2001
Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.. 45. 2001
Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.. 45. 2001
Antimicrobial susceptibility of Ehrlichia phagocytophila.. 45. 2001
Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI and Cecropin P1.. 45. 2001
Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.. 45. 2001
Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.. 45. 2001
Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine.. 44. 2000
Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group.. 44. 2000
Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits.. 44. 2000
Activities of poloxamer CRL-1072 against Mycobacterium avium in macrophage culture and in mice.. 43. 1999
Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996.. 43. 1999
Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits.. 43. 1999
Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.. 43. 1999
In vitro activity of HSR-903, a new oral quinolone, against bacteria causing respiratory infections.. 43. 1999
Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection.. 43. 1999
Pharmacokinetics of oral zidovudine entrapped in biodegradable nanospheres in rabbits.. 43. 1999
Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.. 42. 1998
Compartmental pharmacokinetics and tissue drug distribution of the pradimicin derivative BMS 181184 in rabbits.. 42. 1998
Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography.. 42. 1998
Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci.. 42. 1998
Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants.. 41. 1997
Abnormal physiological properties and altered cell wall composition in Streptococcus pneumoniae grown in the presence of clavulanic acid.. 41. 1997
Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.. 40. 1996
Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis.. 40. 1996
Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography.. 40. 1996
Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo.. 39. 1995
Antimicrobial activities of beta-lactam antibiotics and gentamicin against penicillin-susceptible and penicillin-resistant pneumococci.. 39. 1995
SHV-7, a novel cefotaxime-hydrolyzing beta-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients.. 39. 1995
Treatment of exogenous Candida endophthalmitis in rabbits with oral fluconazole.. 39. 1995
Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in Staphylococcus aureus.. 38. 1994
Low-dose dexamethasone as adjunctive therapy for disseminated Mycobacterium avium complex infections in AIDS patients.. 38. 1994
Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit.. 38. 1994
Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.. 38. 1994
Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography.. 37. 1993
Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine.. 37. 1993
Pharmacokinetics of 18F-labeled fleroxacin in rabbits with Escherichia coli infections, studied with positron emission tomography.. 36. 1992
Multiple mechanisms of methicillin resistance and improved methods for detection in clinical isolates of Staphylococcus aureus.. 35. 1991
Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci.. 35. 1991
Discrimination of extended-spectrum beta-lactamases by a novel nitrocefin competition assay.. 34. 1990
Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy beta-lactams in clinical isolates of Klebsiella pneumoniae.. 34. 1990
Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility.. 34. 1990
Insertional inactivation of the mec gene in a transposon mutant of a methicillin-resistant clinical isolate of Staphylococcus aureus.. 34. 1990
Two bactericidal targets for penicillin in pneumococci: autolysis-dependent and autolysis-independent killing mechanisms.. 34. 1990
New mechanism for methicillin resistance in Staphylococcus aureus: clinical isolates that lack the PBP 2a gene and contain normal penicillin-binding proteins with modified penicillin-binding capacity.. 33. 1989
Modulation of bacteriolysis by cooperative effects of penicillin-binding proteins 1a and 3 in Escherichia coli.. 30. 1986
Beta-lactam-specific resistant mutants of Staphylococcus aureus.. 30. 1986
Penicillin-binding proteins of penicillin-susceptible and -resistant pneumococci: immunological relatedness of altered proteins and changes in peptides carrying the beta-lactam binding site.. 30. 1986
Alterations in kinetic properties of penicillin-binding proteins of penicillin-resistant Streptococcus pneumoniae.. 30. 1986
Evaluation of the bactericidal activity of beta-lactam antibiotics on slowly growing bacteria cultured in the chemostat.. 29. 1986
In vitro activities of selected new and long-acting cephalosporins against Pasteurella multocida.. 29. 1986
Expression of methicillin resistance in heterogeneous strains of Staphylococcus aureus.. 29. 1986
Effects of apalcillin on platelet function in normal volunteers.. 27. 1985
Response of Legionella pneumophila to beta-lactam antibiotics.. 27. 1985
Protection by D-amino acids against growth inhibition and lysis caused by beta-lactam antibiotics.. 26. 1984
Differences in susceptibilities of species of the Bacteroides fragilis group to several beta-lactam antibiotics: indole production as an indicator of resistance.. 22. 1982
Penicillin-resistant and penicillin-tolerant mutants of group A Streptococci.. 22. 1982
Structural and phenotypic varieties of gentamicin resistance plasmids in hospital strains of Staphylococcus aureus and coagulase-negative staphylococci.. 21. 1982
Minimal nephrotoxicity with cephalosporin-aminoglycoside combinations in patients with neoplastic disease.. 21. 1982
Competition of beta-lactam antibiotics for the penicillin-binding proteins of Neisseria gonorrhoeae.. 20. 1981
pH-dependent penicillin tolerance of group B streptococci.. 20. 1981
Altered penicillin-binding proteins in methicillin-resistant strains of Staphylococcus aureus.. 19. 1981
Hypersusceptibility of penicillin-treated group B streptococci to bactericidal activity of human polymorphonuclear leukocytes.. 19. 1981
Physiological properties of penicillin-binding proteins in group A streptococci.. 19. 1981
Effects of sodium piperacillin on platelet function in normal volunteers.. 19. 1981
Penicillin-binding proteins of penicillin-susceptible and intrinsically resistant Neisseria gonorrhoeae.. 18. 1980
In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae.. 18. 1980
Multiple changes of penicillin-binding proteins in penicillin-resistant clinical isolates of Streptococcus pneumoniae.. 17. 1980
Penicillin-binding proteins of multiply antibiotic-resistant South African strains of Streptococcus pneumoniae.. 17. 1980
Lethal effect of a heterologous murein hydrolase on penicillin-treated Streptococcus sanguis.. 17. 1980
Triggering of autolytic cell wall degradation in Escherichia coli by beta-lactam antibiotics.. 16. 1979
In vitro activity of Sch 21420, derivative of gentamicin B, compared to that of amikacin.. 14. 1978
In vitro activity of 5-episisomicin in bacteria resistant to other aminoglycoside antibiotics.. 14. 1978
Nafcillin therapy for Staphylococcus aureus endocarditis.. 14. 1978
Effect of benzylpenicillin on the synthesis and structure of the cell envelope of Neisseria gonorrhoeae.. 13. 1978
Infections due to gentamicin-resistant Staphylococcus aureus strain in a nursery for neonatal infants.. 13. 1978
Characterization of cell wall polymers secreted into the growth medium of lysis-defective pneumococci during treatment with penicillin and other inhibitors of cell wall synthesis.. 13. 1978
Secretion of cell wall polymers into the growth medium of lysis-defective pneumococci during treatment with penicillin and other inhibitors of cell wall synthesis.. 13. 1978
Tolerant response of Streptococcus sanguis to beta-lactams and other cell wall inhibitors.. 11. 1977
Suppression of the lytic and bactericidal effects of cell wallinhibitory antibiotics.. 10. 1976
In vitro comparison of netilmicin, a semisynthetic derivative of sisomicin, and four other aminoglycoside antibiotics.. 10. 1976
Influence of cephalosporin antibiotics on blood coagulation and platelet function.. 9. 1976
Study of the effects of ticarcillin on blood coagulation and platelet function.. 7. 1975
Gentamicin-adenylyltransferase activity as a cause of gentamicin resistance in clinical isolates of Pseudomonas aeruginosa.. 5. 1974
Treatment of chronic typhoid carriers with ampicillin.. 3. 1973
Community-associated Escherichia coli harboring CTX-M β-lactamases from urine cultures from pediatric patients.. 56. 2012
Questionable susceptibility reporting in a multicenter trial.. 39. 1995
Treatment of severe pneumonia with ciprofloxacin or imipenem.. 38. 1994
Klebsiella pneumoniae isolate producing at least eight different beta-lactamases, including AmpC and KPC beta-lactamases. 2006
In vitro activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. 2006
Effect of novobiocin-containing antimicrobial regimens on infection and colonization with vancomycin-resistant Enterococcus faecium. 1995
Antibiotic tolerance among clinical isolates of bacteria. 1986

VIVO Weill Cornell Medical College

Antimicrobial agents and chemotherapy Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)